X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2352) 2352
Publication (174) 174
Book Chapter (30) 30
Book Review (15) 15
Dissertation (11) 11
Book / eBook (5) 5
Newspaper Article (2) 2
Conference Proceeding (1) 1
Data Set (1) 1
Journal / eJournal (1) 1
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1350) 1350
oncology (1081) 1081
index medicus (997) 997
female (976) 976
male (895) 895
middle aged (879) 879
aged (795) 795
chemotherapy (743) 743
adult (739) 739
treatment outcome (527) 527
antineoplastic combined chemotherapy protocols - therapeutic use (525) 525
cancer (494) 494
second-line chemotherapy (485) 485
docetaxel (374) 374
second-line therapy (361) 361
second-line (346) 346
lung neoplasms - drug therapy (323) 323
second-line treatment (299) 299
care and treatment (296) 296
cisplatin (294) 294
therapy (277) 277
trial (270) 270
aged, 80 and over (255) 255
carcinoma, non-small-cell lung - drug therapy (243) 243
gemcitabine (243) 243
retrospective studies (241) 241
medicine & public health (236) 236
second line (234) 234
antineoplastic agents - therapeutic use (233) 233
disease-free survival (231) 231
survival (229) 229
antineoplastic combined chemotherapy protocols - adverse effects (220) 220
drug therapy (215) 215
paclitaxel (213) 213
irinotecan (212) 212
pharmacology & pharmacy (203) 203
survival rate (194) 194
drug administration schedule (186) 186
combination (182) 182
survival analysis (176) 176
metastasis (174) 174
research (171) 171
analysis (170) 170
infectious diseases (168) 168
neoplasm staging (165) 165
deoxycytidine - analogs & derivatives (163) 163
prognosis (163) 163
respiratory system (162) 162
treatment failure (162) 162
lung neoplasms - pathology (161) 161
carcinoma (158) 158
phase-iii trial (158) 158
disease progression (157) 157
oxaliplatin (156) 156
phase-ii trial (155) 155
supportive care (149) 149
non-small cell lung cancer (148) 148
drug resistance, neoplasm (142) 142
hematology, oncology and palliative medicine (140) 140
phase-ii (139) 139
neoplasm metastasis (137) 137
clinical trials (136) 136
camptothecin - analogs & derivatives (135) 135
salvage therapy (132) 132
neoplasm recurrence, local - drug therapy (129) 129
efficacy (128) 128
open-label (128) 128
bevacizumab (127) 127
carcinoma, non-small-cell lung - pathology (124) 124
patients (124) 124
deoxycytidine - administration & dosage (123) 123
antineoplastic agents (119) 119
paclitaxel - administration & dosage (119) 119
5-fluorouracil (117) 117
fluorouracil (117) 117
cancer research (116) 116
antimitotic agents (115) 115
carboplatin (115) 115
health aspects (115) 115
adenocarcinoma - drug therapy (114) 114
lung neoplasms - mortality (112) 112
lung cancer, non-small cell (111) 111
taxoids - administration & dosage (111) 111
camptothecin - administration & dosage (110) 110
gastroenterology & hepatology (110) 110
young adult (110) 110
cisplatin - administration & dosage (108) 108
drug resistance (107) 107
antineoplastic combined chemotherapy protocols - administration & dosage (105) 105
fluorouracil - administration & dosage (105) 105
pemetrexed (104) 104
drug therapy, combination (103) 103
erlotinib (103) 103
kaplan-meier estimate (103) 103
randomized-trial (103) 103
adolescent (102) 102
multicenter (102) 102
follow-up studies (101) 101
stomach neoplasms - drug therapy (100) 100
vinorelbine (100) 100
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2160) 2160
German (72) 72
French (52) 52
Japanese (31) 31
Korean (26) 26
Russian (23) 23
Spanish (16) 16
Chinese (15) 15
Polish (7) 7
Turkish (6) 6
Italian (5) 5
Czech (4) 4
Portuguese (4) 4
Hungarian (3) 3
Indonesian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LONG TERM ORAL ETOPOSIDE AS SECOND-LINE THERAPY IN RECURRENT EPITHELIAL CARCINOMA OF THE OVARY, 12/2005
Background: The activity and toxicity of etoposide in women with recurrent ovarian cancer was evaluated in a case series of women with recurrent ovarian cancer... 
Oral etoposide, recurrent epithelial ovarian cancer, second-line chemotherapy
Journal
Lung Cancer Management, ISSN 1758-1966, 12/2019, Volume 8, Issue 3, p. LMT15
Aim: The current study evaluated the efficacy and tolerability of second-line afatinib in patients with EGFR mutation-positive ( EGFRm+) non-small-cell lung... 
Journal Article
Medicina Clinica, ISSN 0025-7753, 04/2016, Volume 146, pp. 19 - 24
After description of the importance of EGFR mutations in non-small cell lung cancer and confirmation that tyrosine-kinase inhibitors are more beneficial than... 
Afatinib | Second-line | EGFR
Journal Article
International Journal of Tuberculosis and Lung Disease, ISSN 1027-3719, 08/2018, Volume 22, Issue 8, pp. 899 - 904
Journal Article
Annals of Oncology, ISSN 0923-7534, 11/2013, Volume 24, Issue 11, pp. 2850 - 2854
Journal Article
ISSN 1758-1966, 12/2019, Volume 8, Issue 3
The current study evaluated the efficacy and tolerability of second-line afatinib in patients with mutation-positive ( m+) non-small-cell lung cancer (NSCLC)... 
afatinib | second line | EGFR
Journal Article
Journal of Clinical Gastroenterology, ISSN 0192-0790, 04/2019, Volume 53, Issue 4, pp. 251 - 261
Journal Article
Cancer, ISSN 0008-543X, 04/2011, Volume 117, Issue 7, pp. 1422 - 1428
BACKGROUND: Small bowel adenocarcinoma (SBA) is a rare tumor with poor prognosis. First‐line platinum‐based chemotherapy is active in patients with advanced... 
advanced small bowel adenocarcinoma | chemotherapy | second line | survival | FOLFIRI
Journal Article
Cancer, ISSN 0008-543X, 12/2019, Volume 125, Issue 24, pp. 4426 - 4434
Background Although gemcitabine plus platinum chemotherapy is the established first‐line regimen for advanced biliary cancer (ABC), there is no standard... 
gallbladder cancer | bile duct cancer | biliary cancer | chemotherapy | cholangiocarcinoma | second line
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 11/2018, Volume 13, Issue 11, pp. 1784 - 1791
There is no approved second-line treatment for malignant pleural mesothelioma (MPM). On the basis of promising early results, pembrolizumab was used off-label... 
Mesothelioma | Pembrolizumab | PD-1 | Immunotherapy | Second-line therapy | THERAPY | ONCOLOGY | RESPIRATORY SYSTEM | 2ND
Journal Article
Journal of Gastrointestinal Cancer, ISSN 1941-6628, 2018, Volume 50, Issue 4, pp. 860 - 866
Advanced pancreatic adenocarcinoma (PA) is an aggressive disease that has poor prognosis and frequently interferes with patient's quality of life. There has... 
Second-line treatment | FOLFIRINOX | Gemcitabine | Pancreatic
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 01/2020, Volume 22, Issue 1, pp. 59 - 65
Aims To investigate whether combinations of routinely available clinical features can predict which patients are likely to be non‐adherent to diabetes... 
Type 2 diabetes | treatment | second‐line | adherence | compliance | therapy | medication | medical possession ratio | Original
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.